As of 2025-07-06, the EV/EBITDA ratio of Jeil Pharma Holdings Inc (002620.KS) is 22.19. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 002620.KS's latest enterprise value is 247,759.40 mil KRW. 002620.KS's TTM EBITDA according to its financial statements is 11,163.10 mil KRW. Dividing these 2 quantities gives us the above 002620.KS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative Enterprise Value.
| Range | Selected | |
| Trailing P/E multiples | 5.0x - 7.1x | 5.6x |
| Forward P/E multiples | 4.9x - 6.7x | 5.6x |
| Fair Price | (3,296.89) - (1,717.14) | (2,762.15) |
| Upside | -137.4% - -119.5% | -131.3% |
| Date | EV/EBITDA |
| 2025-04-29 | 20.89 |
| 2025-04-28 | 20.86 |
| 2025-04-25 | 21.01 |
| 2025-04-24 | 21.02 |
| 2025-04-23 | 21.02 |
| 2025-04-22 | 20.96 |
| 2025-04-21 | 21.09 |
| 2025-04-18 | 20.88 |
| 2025-04-17 | 20.88 |
| 2025-04-16 | 20.79 |
| 2025-04-15 | 20.88 |
| 2025-04-14 | 20.85 |
| 2025-04-11 | 20.68 |
| 2025-04-10 | 20.33 |
| 2025-04-09 | 19.91 |
| 2025-04-08 | 20.01 |
| 2025-04-07 | 19.82 |
| 2025-04-04 | 20.86 |
| 2025-04-03 | 21.19 |
| 2025-04-02 | 21.19 |
| 2025-04-01 | 20.98 |
| 2025-03-31 | 21.58 |
| 2025-03-28 | 20.78 |
| 2025-03-27 | 20.65 |
| 2025-03-26 | 20.55 |
| 2025-03-25 | 20.84 |
| 2025-03-24 | 20.45 |
| 2025-03-21 | 20.45 |
| 2025-03-20 | 20.53 |
| 2025-03-19 | 20.76 |
| 2025-03-18 | 21.59 |
| 2025-03-17 | 20.06 |
| 2025-03-14 | 20.16 |
| 2025-03-13 | 20.09 |
| 2025-03-12 | 20.12 |
| 2025-03-11 | 20.06 |
| 2025-03-10 | 20.16 |
| 2025-03-07 | 20.05 |
| 2025-03-06 | 20.01 |
| 2025-03-05 | 19.86 |
| 2025-03-04 | 19.62 |
| 2025-02-28 | 19.95 |
| 2025-02-27 | 20.09 |
| 2025-02-26 | 20.09 |
| 2025-02-25 | 19.89 |
| 2025-02-24 | 20.02 |
| 2025-02-21 | 20.08 |
| 2025-02-20 | 20.09 |
| 2025-02-19 | 19.95 |
| 2025-02-18 | 20.05 |